Salivary flow rate · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Side effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Taste disturbance (severe, > 2 on 0-3 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Polaprezinc led to lower taste disturbance (severe, > 2 on 0-3 scale) compared with azulene oral rinse; GRADE not reported.
1 finding from 1 review
Xerostomia (severe) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Polaprezinc led to lower xerostomia (severe) compared with azulene oral rinse; GRADE not reported.
1 finding from 1 review
Change in grip strength · patients with chronic inflammatory demyelinating polyradiculoneuropathy
1 finding from 1 review
Sleeplessness · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone may leads to lower sleeplessness compared with oral prednisolone (low certainty).
1 finding from 1 review
Moon facies · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone probably leads to lower moon facies compared with oral prednisolone (moderate certainty).
1 finding from 1 review
Change in disability after one year · patients with chronic inflammatory demyelinating polyradiculoneuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Remission · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone probably leads to higher remission at 12 months compared with oral prednisolone (moderate certainty).
1 finding from 1 review
≥ 1 point improvement on INCAT disability score at 12 months · patients with chronic inflammatory demyelinating polyradiculoneuropathy
Monthly pulsed high‐dose dexamethasone may leads to higher ≥ 1 point improvement on INCAT disability score at 12 months compared with oral prednisolone (low certainty).
1 finding from 1 review
Change in MRC sum score · patients with chronic inflammatory demyelinating polyradiculoneuropathy
1 finding from 1 review
Symptomatic improvement · adults with dry eye syndrome
It is very uncertain whether summary of findings: punctal plugs changes symptomatic improvement compared with oral pilocarpine (very low certainty).
1 finding from 1 review
Ocular surface staining · adults with dry eye syndrome
1 finding from 1 review
Aqueous tear production · adults with dry eye syndrome
1 finding from 1 review
Tear film stability · adults with dry eye syndrome
The review found no eligible studies for this question.
1 finding from 1 review
Artificial tear use · adults with dry eye syndrome
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events · adults with dry eye syndrome
1 finding from 1 review
Intervention not reported
Seizure freedom (1‐ to 3‐month blinded evaluation periods) · patients with refractory medial temporal lobe epilepsy
The intervention showed no clear difference in seizure freedom (1‐ to 3‐month blinded evaluation periods) (moderate certainty).
1 finding from 1 review
Intervention not reported
Responder rate (1‐ to 3‐month blinded evaluation periods) · patients with refractory medial temporal lobe epilepsy
The intervention showed no clear difference in responder rate (1‐ to 3‐month blinded evaluation periods) (low certainty).
1 finding from 1 review